

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: [year=2007; month=12; day=13; hr=9; min=43; sec=6; ms=958;]

=====

Application No: 10077624 Version No: 3.0

Input Set:**Output Set:**

Started: 2007-11-26 09:38:22.663
Finished: 2007-11-26 09:38:26.354
Elapsed: 0 hr(s) 0 min(s) 3 sec(s) 691 ms
Total Warnings: 28
Total Errors: 0
No. of SeqIDs Defined: 31
Actual SeqID Count: 31

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
W 213	Artificial or Unknown found in <213> in SEQ ID (19)
W 213	Artificial or Unknown found in <213> in SEQ ID (20)
W 213	Artificial or Unknown found in <213> in SEQ ID (21)
W 213	Artificial or Unknown found in <213> in SEQ ID (22)
W 213	Artificial or Unknown found in <213> in SEQ ID (23)

Input Set:

Output Set:

Started: 2007-11-26 09:38:22.663
Finished: 2007-11-26 09:38:26.354
Elapsed: 0 hr(s) 0 min(s) 3 sec(s) 691 ms
Total Warnings: 28
Total Errors: 0
No. of SeqIDs Defined: 31
Actual SeqID Count: 31

Error code

Error Description

This error has occurred more than 20 times, will not be displayed

SEQUENCE LISTING

<110> Shi, Wenyuan
 Morrison, Sherie
 Trinh, Kham
 Wims, Letitia
 Chen, Li
 Anderson, Maxwell
 Qi, Fengxia

<120> Anti-Microbial Targeting Chimeric Pharmaceutical

<130> 59157.8007.US01

<140> 10077624
 <141> 2002-02-14

<150> US 09/910,358
 <151> 2001-07-19

<150> US 09/378,577
 <151> 1999-08-20

<160> 31

<170> PatentIn version 3.4

<210> 1
 <211> 563
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Histatin 5/linker peptide/SWLA3 VH chain construct synthesized
 using sequential PCR techniques

<220>
 <221> misc_feature
 <222> (69)..(140)
 <223> Histatin 5 peptide

<220>
 <221> misc_feature
 <222> (141)..(188)
 <223> Glycine/serine linker peptide

<400> 1
 ggatatccac catggacttc gggttgagct tggttttcct tgtccttact ttaaaaggtg 60
 tccagtgtga tagccacgct aagcggcacc acggatataa gcggaagttc cacgagaagc 120
 accactcgca cagaggatac tctggtggcg gtggctcggg cggaggtggg tcgggtggcg 180
 gcggatccga cgtgaagctt gtggagtctg ggggaggctt agtgaaccct ggaggggtccc 240

```

tgaaactctc ctgtgcagcc tctggattca ctttcagtag ctataccatg tcttgggttc      300
gccagactcc ggagaagagg ctggagtggg tcgcatccat tagtagtggt ggtacttaca      360
cctactatcc agacagtgtg aagggccgat tcaccatctc cagagacaat gccaagaaca      420
ccctgtacct gcaaatagacc agtctgaagt ctgaggacac agccatgtat tactgttcaa      480
gagatgacgg ctccacggc tcctattact atgctatgga ctactggggg caaggaacct      540
cagtcaccgt ctcttcagct agc                                              563

```

```

<210>  2
<211> 24
<212>  PRT
<213> Homo sapiens

```

```

<400>  2

```

```

Asp Ser His Ala Lys Arg His His Gly Tyr Lys Arg Lys Phe His Glu
1           5           10           15

```

```

Lys His His Ser His Arg Gly Tyr
          20

```

```

<210>  3
<211> 16
<212>  PRT
<213> Artificial sequence

```

```

<220>
<223> Linker peptide used to separate antimicrobial peptides from
      antibody VH chains in chimeric antibody fusion protein constructs

```

```

<400>  3

```

```

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1           5           10           15

```

```

<210>  4
<211> 165
<212>  PRT
<213> Artificial sequence

```

```

<220>
<223> Histatin 5/linker peptide/SWLA3 VH chain construct synthesized
      using sequential PCR techniques

```

```

<220>
<221> MISC_FEATURE
<222> (1)..(24)
<223> Histatin 5 peptide

```

```

<220>
<221>  MISC_FEATURE
<222>  (25)..(40)
<223>  Glycine/serine linker peptide

<400>  4

Asp Ser His Ala Lys Arg His His Gly Tyr Lys Arg Lys Phe His Glu
1              5              10              15

Lys His His Ser His Arg Gly Tyr Ser Gly Gly Gly Gly Ser Gly Gly
              20              25              30

Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Lys Leu Val Glu Ser Gly
              35              40              45

Gly Gly Leu Val Asn Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala
              50              55              60

Ser Gly Phe Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Thr
65              70              75              80

Pro Glu Lys Arg Leu Glu Trp Val Ala Ser Ile Ser Ser Gly Gly Thr
              85              90              95

Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg
              100              105              110

Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Thr Ser Leu Lys Ser
              115              120              125

Glu Asp Thr Ala Met Tyr Tyr Cys Ser Arg Asp Asp Gly Ser Tyr Gly
              130              135              140

Ser Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr
145              150              155              160

Val Ser Ser Ala Ser
              165

<210>  5
<211>  533
<212>  DNA
<213>  Artificial sequence

```

<220>

<223> Dhvar 1/linker peptide/SWLA3 VH chain construct synthesized using sequential PCR techniques

<220>

<221> misc_feature

<222> (69)..(110)

<223> Dhvar 1 peptide

<220>

<221> misc_feature

<222> (111)..(158)

<223> Glycine/serine linker peptide

<400> 5

ggatatccac catggacttc gggttgagct tggttttcct tgtccttact ttaaaaggtg 60

tccagtgtaa gcggctgttt aaggagctca agttcagcct gcgcaagtac tctggtggcg 120

gtggctcggg cggaggtggg tcgggtggcg gcggatccga cgtgaagctt gtggagtctg 180

ggggaggctt agtgaaccct ggagggctcc tgaaactctc ctgtgcagcc tctggattca 240

ctttcagtag ctataccatg tcttgggttc gccagactcc ggagaagagg ctggagtggg 300

tcgcattccat tagtagtggg ggtacttaca cctactatcc agacagtgtg aagggccgat 360

tcaccatctc cagagacaat gccaagaaca ccctgtacct gcaaatgacc agtctgaagt 420

ctgaggacac agccatgtat tactgttcaa gagatgacgg ctccctacggc tcctattact 480

atgctatgga ctactggggg caaggaacct cagtcaccgt ctcttcagct agc 533

<210> 6

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic antimicrobial peptide based on histatin 5

<400> 6

Lys Arg Leu Phe Lys Glu Leu Lys Phe Ser Leu Arg Lys Tyr

1 5 10

<210> 7

<211> 155

<212> PRT

<213> Artificial sequence

<220>

<223> Dhvar 1/linker peptide/SWLA3 VH chain construct synthesized using sequential PCR techniques

<220>
<221> MISC_FEATURE
<222> (1)..(14)
<223> Dhvar 1 peptide

<220>
<221> MISC_FEATURE
<222> (15)..(30)
<223> Glycine/serine linker peptide

<400> 7

Lys Arg Leu Phe Lys Glu Leu Lys Phe Ser Leu Arg Lys Tyr Ser Gly
1 5 10 15

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val
20 25 30

Lys Leu Val Glu Ser Gly Gly Gly Leu Val Asn Pro Gly Gly Ser Leu
35 40 45

Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Thr Met
50 55 60

Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Ser
65 70 75 80

Ile Ser Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly
85 90 95

Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln
100 105 110

Met Thr Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ser Arg
115 120 125

Asp Asp Gly Ser Tyr Gly Ser Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
130 135 140

Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser
145 150 155

<210> 8
<211> 89
<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer used to generate histatin 5/SWLA3 chimeric antibody fusion protein construct

<400> 8

caccactcgc acagaggata ctctggtggc ggtggctcgg gcggagggtgg gtcggggtggc 60

ggcgggatacgc acgtgaagct tgtggagtc 89

<210> 9

<211> 84

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer used to generate histatin 5/SWLA3 chimeric antibody fusion protein construct

<400> 9

ggtgtccagt gtgatagcca cgctaagcgg caccacggat ataagcggaa gttccacgag 60

aagcaccact cgcacagagg atac 84

<210> 10

<211> 74

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer used to generate histatin 5/SWLA3 chimeric antibody fusion protein construct

<400> 10

gatatccacc atggacttcg ggttgagctt ggttttcctt gtccttactt taaaagggtgt 60

ccagtgtgat agcc 74

<210> 11

<211> 87

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer used to generate dhvar 1/SWLA3 chimeric antibody fusion protein construct

<400> 11

gttcagcctg cgcaagtact ctggtggcgg tggctcgggc ggagggtgggt cgggtggcgg 60

cggatccgac gtgaagcttg tggagtc 87

<210> 12
 <211> 69
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> PCR primer used to generate dhvar 1/SWLA3 chimeric antibody
 fusion protein construct

 <400> 12
 gtccttactt taaaaggtgt ccagtgtgaag cggctgttta aggagctcaa gttcagcctg 60

 cgcaagtac 69

<210> 13
 <211> 65
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> PCR primer used to generate dhvar 1/SWLA3 chimeric antibody
 fusion protein construct

 <400> 13
 ggatatccac catggacttc gggttgagct tggttttcct tgtccttact ttaaaaggtg 60

 tccag 65

<210> 14
 <211> 39
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> PCR primer used to generate histatin 5/SWLA3 and dhvar 1/SWLA3
 chimeric antibody fusion protein constructs

 <400> 14
 tgggtcgacw gatgggggstg ttgtgctagc tgaggagac 39

<210> 15
 <211> 18
 <212> PRT
 <213> Sus scrofa

 <400> 15

 Arg Gly Gly Arg Leu Cys Tyr Cys Arg Arg Arg Phe Cys Val Cys Val
 1 5 10 15

 Gly Arg

<210> 16
<211> 57
<212> DNA
<213> Sus scrofa

<400> 16
aggggagggtc gcctgtgcta ttgtaggcgt aggttctgcg tctgtgtcgg acgagga 57

<210> 17
<211> 18
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic antimicrobial peptide based on Ovis aries SMAP-29

<400> 17

Lys	Asn	Leu	Arg	Arg	Ile	Ile	Arg	Lys	Gly	Ile	His	Ile	Ile	Lys	Lys
1				5					10					15	

Tyr Gly

<210> 18
<211> 36
<212> DNA
<213> Artificial sequence

<220>
<223> Forward primer for amplification of protegrin PG-1

<220>
<221> misc_feature
<222> (8)..(15)
<223> SapI restriction enzyme cleavage site

<400> 18
ggtggttgct cttccaacag gggaggtcgc ctgtgc 36

<210> 19
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Reverse primer for amplification of protegrin PG-1

<220>
<221> misc_feature

<222> (3)..(8)
<223> BamHI restriction enzyme cleavage site

<400> 19
ccggatcctc gtccgacaca gac 23

<210> 20
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Forward primer for amplification of glycine/serine linker

<400> 20
ggggatccgg tggcggtggc tcg 23

<210> 21
<211> 26
<212> DNA
<213> Artificial sequence

<220>
<223> Reverse primer for amplification of glycine/serine linker

<220>
<221> misc_feature
<222> (4)..(9)
<223> ClaI restriction enzyme cleavage site

<400> 21
aacatcgata gatccgccgc caccgc 26

<210> 22
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Forward primer for amplification of SWLA3 VL chain

<220>
<221> misc_feature
<222> (3)..(8)
<223> ClaI restriction enzyme cleavage site

<400> 22
ggatcgatgt tgtgatgacc cag 23

<210> 23
<211> 31

<212> DNA
<213> Artificial sequence

<220>
<223> Reverse primer for amplification of SWLA3 VL chain

<220>
<221> misc_feature
<222> (5)..(10)
<223> SalI restriction enzyme cleavage site

<400> 23
gcggggtcgac cgacttacgt ttcagctcca g

31

<210> 24
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Forward primer for amplification of SWLA3 VH chain

<220>
<221> misc_feature
<222> (5)..(10)
<223> SalI restriction enzyme cleavage site

<400> 24
gcggggtcgac gtgaagctgg tggagtctg

29

<210> 25
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> Reverse primer for amplification of SWLA3 VH chain

<220>
<221> misc_feature
<222> (10)..(15)
<223> NheI restriction enzyme cleavage site

<400> 25
gggtggtgag ctagctgaag agacggtgac

30

<210> 26
<211> 24
<212> PRT
<213> Artificial sequence

<220>

<223> Synthetic linker for use in protegrin fusion protein

<400> 26

Leu Asp Pro Lys Ser Cys Glu Arg Ser His Ser Cys Pro Pro Cys Gly
1 5 10 15

Gly Gly Ser Gly Gly Gly Thr Ser
20

<210> 27
<211> 72
<212> DNA
<213> Artificial sequence

<220>

<223> Synthetic linker for use in protegrin fusion protein

<400> 27

ctcgacccaa agagctgcga gcggagccac agctgccac cgtgcggggg tgggtccggc 60

ggtggcacta gt 72

<210> 28
<211> 28
<212> DNA
<213> Artificial sequence

<220>

<223> Forward primer for amplification of SWLA3 VH chain/CH3 linker

<220>

<221> misc_feature
<222> (5)..(10)
<223> NheI restriction enzyme cleavage site

<400> 28

gtgggctagc ctcgacccaa agagctgc 28

<210> 29
<211> 38
<212> DNA
<213> Artificial sequence

<220>

<223> Reverse primer for amplification of SWLA3 VH chain/CH3 linker

<400> 29

aggttctcgg ggctgccac tagtgccacc gccggacc 38

<210> 30
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Forward primer for amplification of human CH3 gene fragment

<400> 30
gggcagcccc gagaacaac 19

<210> 31
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> Reverse primer for amplification of human CH3 gene fragment

<220>
<221> misc_feature
<222> (7)..(12)
<223> PstI restriction enzyme cleavage site

<400> 31
ggtggtctgc agtttaccgc gggacaggga gag 33